Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379334448> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4379334448 endingPage "7064" @default.
- W4379334448 startingPage "7064" @default.
- W4379334448 abstract "7064 Background: In solid tumours, calreticulin (CALR) overexpression produces a pro-phagocytic signal and is counteracted by concomitant expression of anti- phagocytic CD47, reflecting an apoptosis vs survival mechanism. We have previously found that CD47, not CALR, is overexpressed on the membrane of patients with MPN. Anti-CD47 Magrolimab, is currently being evaluated in clinical trials in AML, MDS but have yet to be tested, either in monotherapy or in combination in MF. Methods: Mononuclear cells were collected by Ficoll separation from bone marrow of 6 MF patients and from 2 controls. CD34+ cells and monocytes were purified using Dynabeads kits from Thermofisher. Cells expression of CALR and CD47 was measured by flow cytometry, before and after incubation with ruxolitinib (Jak inhibitor) alone and in combination with magrolimab. Cells survival was calculated after combining CD34 with monocytes. Informed Consent was obtained for all samples collected. Results: CD47 membrane expression was 57% in untreated MF cells compared to 12% in the control samples and CALR membrane expression was 51.8% in untreated MF cell compared to 12.5% in the control samples. After incubation with ruxolitinib, MF CD34+ cell survival decreased to 98.2%. Following Incubation with magrolimab alone, MF CD34+ cells show no changes in survival (100% alive). The combination of ruxolitinib and magrolimab reduced slightly the MF CD34+ cell survival to 92%. A substantial membrane overexpression of CALR was observed in MF CD34+ cells when incubated with Ruxo and Magrolimab, 74.1%, vs Ruxo alone 52.6%, Magrolimab alone 53.4% and in untreated (51.8%). Interestingly, in the healthy controls, the exposure to combination therapy did not cause the same degree of CALR overexpression (20.7% vs 12.5%), indicating a much stronger pro-phagocytic effect following magrolimab/ruxolitinib combo in MF cancer cells. Conclusions: In vitro, treatment with ruxolitinib or ruxolitinib plus magrolimab, slightly reduce the overall cell survival rate in CD34+ MF samples, comparing with no significant changes in single agent magrolimab. However, the combination of Ruxolitinib and Magrolimab significantly increases CALR membrane expression comparing with Ruxo or Magrolimab alone, signalling a much stronger pro-phagocytic message in MF cells comparing with controls. The induced CALR over-expression, could stimulate a stronger immune response in vivo, where the presence of macrophages would allow removal of CALR rich cells and potentiate the cytoreductive activity towards MF clone. These data support the rational of combining Ruxolitinib with Magrolimab in the next clinical trial stage in myelofibrosis." @default.
- W4379334448 created "2023-06-05" @default.
- W4379334448 creator A5008323158 @default.
- W4379334448 creator A5043246565 @default.
- W4379334448 creator A5069542508 @default.
- W4379334448 date "2023-06-01" @default.
- W4379334448 modified "2023-09-25" @default.
- W4379334448 title "Effects of ruxolitinib and magrolimab on calreticulin in myelofibrosis CD34+ cells in vitro: Proof of concept for combination therapy." @default.
- W4379334448 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.7064" @default.
- W4379334448 hasPublicationYear "2023" @default.
- W4379334448 type Work @default.
- W4379334448 citedByCount "0" @default.
- W4379334448 crossrefType "journal-article" @default.
- W4379334448 hasAuthorship W4379334448A5008323158 @default.
- W4379334448 hasAuthorship W4379334448A5043246565 @default.
- W4379334448 hasAuthorship W4379334448A5069542508 @default.
- W4379334448 hasConcept C10205521 @default.
- W4379334448 hasConcept C126322002 @default.
- W4379334448 hasConcept C137061746 @default.
- W4379334448 hasConcept C158617107 @default.
- W4379334448 hasConcept C159912055 @default.
- W4379334448 hasConcept C160448771 @default.
- W4379334448 hasConcept C202751555 @default.
- W4379334448 hasConcept C203014093 @default.
- W4379334448 hasConcept C2776112149 @default.
- W4379334448 hasConcept C2780007613 @default.
- W4379334448 hasConcept C2780076729 @default.
- W4379334448 hasConcept C2780104668 @default.
- W4379334448 hasConcept C28328180 @default.
- W4379334448 hasConcept C47450691 @default.
- W4379334448 hasConcept C502942594 @default.
- W4379334448 hasConcept C5362183 @default.
- W4379334448 hasConcept C553184892 @default.
- W4379334448 hasConcept C55493867 @default.
- W4379334448 hasConcept C71924100 @default.
- W4379334448 hasConcept C86803240 @default.
- W4379334448 hasConcept C95444343 @default.
- W4379334448 hasConceptScore W4379334448C10205521 @default.
- W4379334448 hasConceptScore W4379334448C126322002 @default.
- W4379334448 hasConceptScore W4379334448C137061746 @default.
- W4379334448 hasConceptScore W4379334448C158617107 @default.
- W4379334448 hasConceptScore W4379334448C159912055 @default.
- W4379334448 hasConceptScore W4379334448C160448771 @default.
- W4379334448 hasConceptScore W4379334448C202751555 @default.
- W4379334448 hasConceptScore W4379334448C203014093 @default.
- W4379334448 hasConceptScore W4379334448C2776112149 @default.
- W4379334448 hasConceptScore W4379334448C2780007613 @default.
- W4379334448 hasConceptScore W4379334448C2780076729 @default.
- W4379334448 hasConceptScore W4379334448C2780104668 @default.
- W4379334448 hasConceptScore W4379334448C28328180 @default.
- W4379334448 hasConceptScore W4379334448C47450691 @default.
- W4379334448 hasConceptScore W4379334448C502942594 @default.
- W4379334448 hasConceptScore W4379334448C5362183 @default.
- W4379334448 hasConceptScore W4379334448C553184892 @default.
- W4379334448 hasConceptScore W4379334448C55493867 @default.
- W4379334448 hasConceptScore W4379334448C71924100 @default.
- W4379334448 hasConceptScore W4379334448C86803240 @default.
- W4379334448 hasConceptScore W4379334448C95444343 @default.
- W4379334448 hasIssue "16_suppl" @default.
- W4379334448 hasLocation W43793344481 @default.
- W4379334448 hasOpenAccess W4379334448 @default.
- W4379334448 hasPrimaryLocation W43793344481 @default.
- W4379334448 hasRelatedWork W1547457247 @default.
- W4379334448 hasRelatedWork W2360726890 @default.
- W4379334448 hasRelatedWork W2391330211 @default.
- W4379334448 hasRelatedWork W2552032031 @default.
- W4379334448 hasRelatedWork W3029052326 @default.
- W4379334448 hasRelatedWork W3031162223 @default.
- W4379334448 hasRelatedWork W4283795688 @default.
- W4379334448 hasRelatedWork W4310106088 @default.
- W4379334448 hasRelatedWork W4313545780 @default.
- W4379334448 hasRelatedWork W4362540291 @default.
- W4379334448 hasVolume "41" @default.
- W4379334448 isParatext "false" @default.
- W4379334448 isRetracted "false" @default.
- W4379334448 workType "article" @default.